Print Page  |  Close Window

Press Releases

Protagonist Therapeutics to Participate in the Leerink Partners 7th Annual Global Healthcare Conference

NEWARK, Calif., Jan. 31, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview at the Leerink Partners 7th Annual Global Healthcare Conference taking place on February 14-15 at the Lotte New York Palace in New York, NY.

Protagonist Therapeutics, Inc. (PRNewsFoto/Protagonist Therapeutics, Inc.)

The Protagonist Therapeutics presentation is scheduled for Wednesday, February 14 at 9:30 am Eastern Time.

A live audio webcast of the presentation may be accessed by visiting the Investors page of Protagonist Therapeutics corporate website at A replay of the presentation will be available for 30 days following the presentation.

About Protagonist Therapeutics

Protagonist Therapeutics is a clinical development-stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to address significant unmet medical needs. Its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. Lead oral peptide candidates, PTG-100 and PTG-200, are based on this approach. The alpha-4-beta-7 integrin antagonist PTG-100 is currently in Phase 2b clinical trials for moderate-to-severe ulcerative colitis, and the company's interleukin-23 receptor antagonist PTG-200 is currently being studied in a Phase 1 clinical trial in healthy volunteers in support of its development as a potential treatment for Crohn's disease.  The company has entered into a worldwide license and collaboration agreement with Janssen Biotech for the clinical development of PTG-200.  Protagonist has also applied its platform to other disease areas and is developing an injectable hepcidin mimetic, PTG-300, for the potential treatment of rare diseases such as beta-thalassemia and myelodysplastic syndromes (MDS). PTG-300 recently completed a Phase 1 clinical trial.

Protagonist is headquartered in Newark, California with pre-clinical and clinical staff in California, and discovery operations both in California and Brisbane, Queensland, Australia. For further information, please visit


Cision View original content with multimedia:

SOURCE Protagonist Therapeutics, Inc.

Joan Kureczka, Bioscribe, Inc., Tel: +1 415-821-2413, Mobile: +1415-690-0210, email:; For Investors: The Trout Group, Marcy Nanus, 646-378-2927,